Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Lee Z, et al. Among authors: flaherty kt. J Urol. 2020 Apr;203(4):684-689. doi: 10.1097/JU.0000000000000588. Epub 2019 Oct 9. J Urol. 2020. PMID: 31596672 Free PMC article.
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Atkins MB, et al. Among authors: flaherty kt. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):667s-670s. doi: 10.1158/1078-0432.CCR-06-2231. Clin Cancer Res. 2007. PMID: 17255291 Review.
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. Choueiri TK, et al. Among authors: flaherty kt. J Clin Oncol. 2013 Jan 10;31(2):181-6. doi: 10.1200/JCO.2012.43.3383. Epub 2012 Dec 3. J Clin Oncol. 2013. PMID: 23213094 Free PMC article. Clinical Trial.
An active learning approach for rapid characterization of endothelial cells in human tumors.
Padmanabhan RK, Somasundar VH, Griffith SD, Zhu J, Samoyedny D, Tan KS, Hu J, Liao X, Carin L, Yoon SS, Flaherty KT, Dipaola RS, Heitjan DF, Lal P, Feldman MD, Roysam B, Lee WM. Padmanabhan RK, et al. Among authors: flaherty kt. PLoS One. 2014 Mar 6;9(3):e90495. doi: 10.1371/journal.pone.0090495. eCollection 2014. PLoS One. 2014. PMID: 24603893 Free PMC article.
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS. Haas NB, et al. Among authors: flaherty kt. Clin Cancer Res. 2015 Sep 15;21(18):4048-54. doi: 10.1158/1078-0432.CCR-15-0215. Epub 2015 May 12. Clin Cancer Res. 2015. PMID: 25967143 Free PMC article. Clinical Trial.
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
Flaherty KT, Manola JB, Pins M, McDermott DF, Atkins MB, Dutcher JJ, George DJ, Margolin KA, DiPaola RS. Flaherty KT, et al. J Clin Oncol. 2015 Jul 20;33(21):2384-91. doi: 10.1200/JCO.2015.60.9727. Epub 2015 Jun 15. J Clin Oncol. 2015. PMID: 26077237 Free PMC article. Clinical Trial.
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Haas NB, et al. Among authors: flaherty kt. Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Lancet. 2016. PMID: 26969090 Free PMC article. Clinical Trial.
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.
Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM. Jilaveanu LB, et al. Among authors: flaherty kt. Clin Cancer Res. 2018 Jan 1;24(1):217-223. doi: 10.1158/1078-0432.CCR-17-1555. Epub 2017 Oct 24. Clin Cancer Res. 2018. PMID: 29066509 Free PMC article. Clinical Trial.
494 results